The subsequent phase 3 CARTITUDE-4 trial compared the efficacy of cilta-cel versus certain SOC regimens in patients with lenalidomide-refractory MM who had received 1-3 prior lines of therapy; of note, anti-CD38 mAb exposure was not required for this study [2]. This evidence concerns the gene CD38 and Miyoshi myopathy.